evidence to this effect, so I would agree with that statement, but the wording here is not entirely clear.
-In general, I think the introduction could be more concise will still capturing the relevant information. -The term "resident physician" is used. In the United States, a resident physician is a physician who is still in training (an MD who is obtaining the additional training needed to practice independently). Is "resident physician" used the same way here or is this an established physician who attends at the NH residence? -Was data collected at entry to the nursing home or at study onset? My impression is that data was collected when the decision was made to run the study, so participants would be at varying places in the duration of their nursing home stay? Please make this clear.
-Were all patients demented? The methods state that dementia diagnoses were made by a resident physician and presumed appropriate, but nowhere does it say that only dementia patients were included. Please confirm that all dementia was an inclusion criterion as this is required when assessing DLB prior to considering the core features. [Update: Table 3 has dementia no/yes, so not all patients were demented. This is a problem. The paper centers around the fact that this cohort may have DLB/LBD but individuals cannot have DLB/LBD if they do not first have dementia. Dementia is the primary inclusion criterion for DLB before any of the core criteria are assessed. I suggest that either (1) you remove the framing mechanism of DLB, since not all patients were demented, (2) you analyze the demented cohort, as dementia + core features is what gets you to DLB, or (3) you reframe the paper to discuss symptoms of Lewy body disease, a pathological entity, though that would also include Parkinson's disease without dementia. Individuals with core features but without dementia cannot be diagnosed as DLB.] Throughout the paper you reference a "DLB group." You can really only reference DLB if those individuals have dementia.
-The patient involvement statement is a little confusing. It states "patients were not involved in the… conduct of this research." The abstract design, though, says this was a prospective observational study. If this was prospective, then presumably there was informed consent (which is indeed noted at the end of the paper), and patients were involved in research conduct as participants? -For "dementia diagnosis," do you have information on which dementia these individuals had? -Please say how many individuals in the cohort had a diagnosis of DLB/LBD; you mention that this data is available -The text seemed to suggest to me that investigators were assessing 4 clinical signs of DLB/LBD (the four DLB clinical core features). The table mentions parkinsonism, fluctuating cognition, visual hallucinations, RBD, balance problems, and rigidity (6 things). Were the 0-2 and 2-4 out of 4 or 6? Please clarify. This is particularly important because rigidity and balance problems are less specific to DLB and can occur for other reasons. Some of the other signs are more diagnostic (which is why they are core vs supportive features). This is underscored by the fact that 31% of patients were thought to be rigid but only 7% were thought to be parkinsonian.
-The references to the prior study with the same population are sometimes confusing. Is the current sample identical to the prior sample? If so, could you not just say that 21% of the current sample was treated with antipsychotics? It is it necessary to reference the prior paper here? The reference to the prior paper makes me confused about whether I should think the same is true here or whether there could be a difference. -When referencing medications, I think the study is specifically describing medications at the point the data was collected, correct? This should be emphasized somewhere. It's not that one cohort had medications and the other didn't, but rather that at the time data was collected, one had medications and the other didn't. Is that right? It could be that patients antipsychotics or antidementia medications were prescribed at other times during the NH stay and that could be missed? Or did you look at all medication/pharmacy records between study onset and death? -It is not clear what the first sentence of the strengths paragraph is supposed to suggest. This sentence seems related to a prior publication? -I would put the information about the face validity of the questionnaire in the methods -A weakness that is not mentioned is the fact that data was collected only at one moment in time. Thus, we only know about symptoms at that moment, about medications at that moment, etc. Also, there is no assessment of the degree of comorbidities that could be a potential confounder.
-You suggest that your confidence in mortality risks is increased because there was no association of antipsychotics with mortality. Why didn't you look at this with a regression model (eg, number of symptoms while controlling for age, gender, and antipsychotic use)? -The use of the term "survival risk" is confusing; it suggests someone is at risk of surviving where the intended meaning is the opposite -The conclusion that "These data support the notion that more thorough dementia investigations of the elderly living in NHs may lead to improved medical treatments and longer survival among this vulnerable population" is not supported. There are no good treatments for fluctuating cognition or balance problems, so identifying these do not have a clear mechanism for prolonging survival. RBD can be treated, but it is likely that RBD symptoms are not leading to mortality but rather that the presence of RBD may represent more widespread or prominent disease. Rigidity can be treatment to some extent if it is parkinsonian rigidity, but this could also represent contractures or deconditioning as can be seen in some individuals in NHs. I see this data as being more helpful for prognostic purposes. -There is useful information in this paper. Knowing that increased clinical features and certain clinical features are associated with increased mortality is helpful for prognostic purposes and can inform additional research.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 Comments Reviewer: 1 Reviewer Name: Christoph Mueller Institution and Country: King's College London, UK Given that that little is known about predictors of mortality in patients with DLB, this is a very relevant study, with a large, generalizable, nursing home population.
Before this can be considered for publication, I few items need to be addressed: 3
Major: It is hard to make conclusions on the survival effects of these symptoms without further adjustment for at least: level of cognitive impairment, some measure of comorbidity, some measure of functioning
We agree, but these data were not available. Therefore, we have added this argument in the discussion under  Survival in the DLB groups 4 2. Evaluating DLB (dementia with Lewy bodies) core features in patients who do not actually have dementia appears slightly odd; an interesting comparison would be Dementia plus DLB 2-4 vs. Dementia plus DLB 0-1 vs. no dementia (could be divided in dementia plus DLB 0-1 and dementia plus DLB 2-4 but might not have sufficient power).
All patients have definitely dementia but a part of them had no formal dementia diagnosis registered in the electronic data system.
We have clarified this in  the method section and the result section. 5 3. Again 26% of the sample do not suffer from dementia; and might thereby have a lower antipsychotic-related mortality risk, making it difficult to interpret findings.
Similarly, patients without dementia are unlikely to be treated with antidementia drugs, influencing these results.
Due to the organisation of the Swedish social welfare system all elderly at dementia nursing homes must have dementia at least at the first diagnostic level (which is registered in the municipality but not available in hospital electronical data system, which we used for data collection). DLB should be the second most common neurodegenerative dementia; and the term disorder in this context might be misleading.
We have omitted "and worsening quality of life (QoL)". Throughout the manuscript the term "disorder" has been removed in this context. 9 6. In discussion, try to avoid the term 'demented' and expand on possible mechanisms of the most important findings.
The term demented is changed to "residents with dementia"
We also added a suggestive mechanism in the end of the discussion.  "as a marker of reduced neurotransmitters due to alfa-synuclein engagement in the nuclei producing these"
Reviewer: 2 Reviewer Name: Melissa J. Armstrong MD, MSc Institution and Country: University of Florida College Medicine, Gainesville, FL, USA -This study looks at predictors of mortality in a nursing home population with features that can be seen in Lewy body dementia.
This study adds important information that can help clinicians assess prognosis of individuals in nursing homes and potentially individuals with Lewy body dementia.
10
My main concern is with the precision with some of the approach in the manuscript.
The authors frequently refer to DLB but not all of the cohort is dementia, which is a prerequisite for applying DLB criteria. It is likely that the paper should also reference Lewy body dementia symptoms/signs, as the timing of onset of cognitive and motor features is unknown.
The conclusions over reach to some extent. There is valuable information here, but some revisions could make the manuscript stronger.
We have clarified this in  the method section and the result section.
Due to the organisation of the Swedish social welfare system, all elderly at dementia nursing homes must have dementia at least at the first diagnostic level (which is registered in the municipality but not available in hospital electronically data system, which we used for data collection).
-Introduction:
Technically, it is Lewy body dementia, not dementia with Lewy bodies, that is the 2nd most common neurodegenerative dementia. This is commonly miswritten. Lewy body dementia includes both DLB and PD dementia. DLB alone probably is not the 2nd most common degenerative dementia.
The main study from which this statistic comes is actually a pathology one diagnosing Lewy body disease by pathology without a clinical diagnosis.
-Because you don't know the relationship between the onset of cognitive and motor symptoms, Lewy body dementia may be a more appropriate term than DLB, where dementia must precede or be concurrent with the parkinsonism onset
We agree about the terminology and have changed DLB  LBD throughout the manuscript.
12
-Introduction: -I'm not entirely clear what is meant by the sentence, "These dementia diseases cause clinical symptoms that may be difficult to differentiate, especially when a clinician suspects an undiagnosed DLB [5] [6] [7] ." Please clarify.
We have (in the background) changed the sentence to  "These dementia diseases cause clinical symptoms that may be difficult to differentiate."
-Introduction:
-This sentence is also somewhat unclear: "Individuals with DLB have a more rapid and aggressive course of dementia, especially if they also have AD pathology with difficult symptomatology and core signs (according to the 2017 DLB criteria) such as: visual hallucinations, parkinsonism, fluctuating cognition and rapid eye movement sleep behaviour disorder (RBD) [8] [9] [10] ." Do you mean to say that DLB progresses more quickly than AD? There is evidence to this effect, so I would agree with that statement, but the wording here is not entirely clear.
-In general, I think the introduction could be more concise will still capturing the relevant information.
"Individuals with DLB have a more rapid and aggressive course of dementia, especially if they also have AD pathology.
with difficult symptomatology and core signs (according to the 2017 DLB criteria) such as: visual hallucinations, parkinsonism, fluctuating cognition and rapid eye movement sleep behaviour disorder (RBD) [8] [9] [10] ." Do you mean to say that DLB progresses more quickly than AD?  No, but when there is concomitant AD pathology.
14 -The term "resident physician" is used. In the United States, a resident physician is a physician who is still in training (an MD who is obtaining the additional training needed to practice independently). Is "resident physician" used the same way here or is this an established physician who attends at the NH residence?
The "resident physician" is used to describe an established physician who attends at the NH residence. Therefore, resident physician is changed to physician throughout the manuscript.
15 -Was data collected at entry to the nursing home or at study onset?
My impression is that data was collected when the decision was made to run the study, so participants would be at varying places in the duration of their nursing home stay? Please make this clear. Please clarify.
The study started as a crosssectional study. We clarified this more in Methods  study design 
The study started as a crosssectional prevalence study. The participants where at different stages of their diseases.
16 -Were all patients demented? The methods state that dementia diagnoses were made by a resident physician and presumed appropriate, but nowhere does it say that only dementia patients were included. Please confirm that all dementia was an inclusion criterion as this is required when assessing DLB prior to considering the core features. Update: Table 3 has dementia no/yes, so not all patients were demented. This is a problem.
Due to the organisation of the Swedish social welfare system, all elderly at dementia nursing homes must have dementia at least at the first diagnostic level (which is registered in the municipality but not available in hospital electronically data system, which we used for data collection). 
18
-The patient involvement statement is a little confusing. It states "patients were not involved in the… conduct of this research." The abstract design, though, says this was a prospective observational study. If this was prospective, then presumably there was informed consent (which is indeed noted at the end of the paper), and patients were involved in research conduct as participants?
We agree and try to clarify by updating the  Patient involvement section  Patients were not involved in the design of the study. However, the patients were involved in the study in the sense that they gave their informed consent to participate.
19
-For "dementia diagnosis," do you have information on which dementia these individuals had?
-Please say how many individuals in the cohort had a diagnosis of DLB/LBD; you mention that this data is available
We described this above ( nr.10 & nr.16).
We agree and therefore added under Discussion  Strengths and limitations of this study  90% (n=13) 20
-The text seemed to suggest to me that investigators were assessing 4 clinical signs of DLB/LBD (the four DLB clinical core features).
The table mentions parkinsonism, fluctuating cognition, visual hallucinations, RBD, balance problems, and rigidity (6 things). Were the 0-2 and 2-4 out of 4 or 6? Please clarify. This is particularly important because rigidity and balance problems are less specific to DLB and can occur for other reasons. Some of the other signs are more diagnostic (which is why they are core vs supportive features). This is underscored by the fact that 31% of patients were thought to be rigid but only 7% were thought to be parkinsonian
To make the judgement easier for the nursing personnel the term parkinsonism was further split into observable parts as rigidity and balance problems. However, it was not considered enough to fulfil the Parkinson-sign only with balance problems. Finally, the complete scoring of signs were evaluated for each patient in consensus by two of the authors.
21
-The references to the prior study with the same population are sometimes confusing. Is the current sample identical to the prior sample? If so, could you not just say that 21% of the current sample was treated with antipsychotics? It is it necessary to reference the prior paper here? The reference to the prior paper makes me confused about whether I should think the same is true here or whether there could be a difference.
We agree that it can be confusing to reference the prior paper and the sentence "However, only one-third of our study population were treated with anti-dementia medication.
(the details of which have been previously published).
[40]" is therefore removed.
22
-When referencing medications, I think the study is specifically describing medications at the point the data was collected, correct? This should be emphasized somewhere.  YES It's not that one cohort had medications and the other didn't, but rather that at the time data was collected, one had medications and the other didn't. Is that right?  YES It could be that patients antipsychotics or anti-dementia medications were prescribed at other times during the NH stay and that could be missed? Or did you look at all medication/pharmacy records between study onset and death?  NO We agree and therefore clarify this more under the method section.
23 -It is not clear what the first sentence of the strengths paragraph is supposed to suggest. This sentence seems related to a prior publication? -I would put the information about the face validity of the questionnaire in the methods.
We understand and therefore try to clarify this more under strengths and limitations.
24 -A weakness that is not mentioned is the fact that data was collected only at one moment in time.
Thus, we only know about symptoms at that moment, about medications at that moment, etc.
Also, there is no assessment of the degree of comorbidities that could be a potential confounder.
We agree. A weakness is that data was collected only at one moment in time.
These data were not available.
25
-You suggest that your confidence in mortality risks is increased because there was no association of antipsychotics with mortality. Why didn't you look at this with a regression model (eg, number of symptoms while controlling for age, gender, and antipsychotic use)?
We have performed a Coxregression analysis controlling for age, gender, all DLB signs as well as for anti-dementia and antipsychotic medication. The results showed the same results as the survival analysis namely that only age and number of DLB signs (0-1 vs 2-4) were significant.
26 -The use of the term "survival risk" is confusing; it suggests someone is at risk of surviving where the intended meaning is the opposite. -The conclusion that "These data support the notion that more thorough dementia investigations of the elderly living in NHs may lead to improved medical treatments and longer survival among this vulnerable population" is not supported.
We agree and change  These data support the notion that more thorough investigations of the LBD signs in elderly living at NHs may lead to improved medical treatments and longer survival among this vulnerable population.
There are no good treatments for fluctuating cognition or balance problems, so identifying these do not have a clear mechanism for prolonging survival. RBD can be treated, but it is likely that RBD symptoms are not leading to mortality but rather that the presence of RBD may represent more widespread or prominent disease. Rigidity can be treatment to some extent if it is parkinsonian rigidity, but this could also represent contractures or deconditioning as can be seen in some individuals in NHs.
I see this data as being more helpful for prognostic purposes.
-There is useful information in this paper.
Knowing that increased clinical features and certain clinical features are associated with increased mortality is helpful for prognostic purposes and can inform additional research.
Thank you for understanding the essence of this paper.
VERSION 2 -REVIEW

REVIEWER
Christoph Mueller
King's College London REVIEW RETURNED 12-Feb-2019
GENERAL COMMENTS
This paper has clearly improved as result of the revisions. It needs however to be clearer about its limitations. Due to lack of adjustment for potential confounders, it cannot be used to claim causation, in particularly not in the pharmaco-epidemiological parts of the study. The focus should really be on the LBD signs -which is the novel bit. Hence, I have to following the following suggestions for the manuscript:
1. Abstract:
Results: I'm not sure whether the study had sufficient power to compare patients with LBD receiving antipsychotic/antidementia drugs (see below) or not -if not, only include a statement about all NH residents.
Conclusions: I'd suggest removing, or at least rewriting the sentence 'We found neighter a negative survival effect of antipsychotics nor a significant positive effect of anti-dementia treatment' as this sentence implies causation, where you can only describe a correlation as you correctly said in the results.
Strength and Limitations:
The reader needs to know the following limitations:
-Cox regression models were only adjusted for age and gender, but not for severity of dementia, co-morbidity, nor functioning -Baseline data for this study was collected cross-sectionally, and participants were at different stages of their disease.
Methods
You described ascertaining ATC codes for anxiolytics, hypnotics/sedatives, anti-depressants, but those were not used in the study. Table 3 shows. It seems to show hazard ratios for mortality in relation to baseline variables, but is labelled 'Mortality risk based on LBD group'. Table 3 also contains a variable about patients suffering from dementia; I thought all patients suffered from dementia. This might refer to a formal diagnosis, but this might not be a very meaningful variable in this data.
Results
It still remains a bit unclear what
I'm not sure whether a stratified analysis for medication hazards/benefits is possible in the LBD groups. E.g. the LBD 2-4 group only consists of 116 patients, and how many of these were actually prescribed an antipsychotic / antidementia drug? If you want to include this analysis, please first check that you have adequate study power to do so -and report in methods. And further whether an interaction exists between LBD group and antidementia drug/antipsychotic prescribing.
Discussion
Again, the study cannot make any conclusions about the treatment with antidementia/antidementia drugs on survival; only the observation that there doesn't seem to appear a difference between receivers / non-receivers of the medications.
This needs to be in particular be mentioned in the discussion chapter 'Survival in relation to medication'.
In Anti-dementia medication: After the sentence 'However, only one-third of our study population were treated with anti-dementia medication. (the details of which have been previously published).
[40]' has been removed the following sentence 'These data demonstrate a major need for improved dementia treatment, …' appears out of context.
Strength and limitations
The aforementioned points need to be added: -Cox regression models were only adjusted for age and gender, but not for severity of dementia, co-morbidity, nor functioning -Baseline data for this study was collected cross-sectionally, and participants were at different stages of their disease.
The statement 'Finally, a finding that increases confidence in our mortality risk results based on number of LBD signs is that antipsychotic treatments did not appear to influence mortality. This supports our hypothesis that survival among elderly patients in the LBD 2-4 group is not influenced by antipsychotics but rather by the signs of LBD as a marker of reduced neurotransmitters due to alfa-synuclein engagement in the nuclei producing these.' still appears very odd. As adverse reactions to antipsychotics are a hallmark of LBD, the finding that patients with LBD didn't have that, it would certainly not increase confidence in the results. I suspect that the finding that antipsychotics don't affect mortality in the LBD 2-4 group is due to a type 2 error, but please check that the study is adequately powered.
Conclusions:
'We did not find a negative effect of antipsychotics on survival.' needs to be toned down. 
REVIEWER
GENERAL COMMENTS
The authors have thoroughly addressed most of the reviewers' comments and the paper is improved while also maintaining its prior relevance. In reviewing the edited manuscripts, the following could benefit from generally minor additional edits.
-In the abstract, suggest rewording to "Mean survival differed between the LBD groups; those with 0-1 LBD signs lived months longer than those with 2-4 LBD signs." This is a minor point. The main suggestion is to reclarify that the number refers to the number of signs, but I also feel that the living longer formulation reads a little easier. This is a very minor point and I am happy to defer to the authors.
-With the addition of HR CIs, the p-value is not needed (minor point, willing to leave to journal editorial discretion, but the CIs include the fact that the HR is statistically significant without the CI) -The meaning of "a high percentage of covering" in strength #2 is not entirely clear -To limitations I would add the cross-sectional nature of initial data collection in addition to the lack of a formal LBD diagnosis -The clarification about the first and second diagnostic levels for dementia diagnosis are very helpful. However, now that the authors clarify that 74% had a formal dementia diagnosis, this raises the question of what this means. If this means a formal etiologic diagnosis (eg AD, LBD, vascular), the percent for each formal diagnosis should be provided. If this means simply that they were formally reported as having dementia, it would be helpful to understand more about how this is different from the first diagnostic level. What is the difference between levels one and two? This is important for readers from different health care contexts to understand how the population in this study compares to the populations in the readers' own clinics.
-The response to reviewers explains the four clinical signs used to count the number of LBD symptoms, but I still don't see this explicitly described in the text. Suggest being explicit about this in the text or the legend with a sentence such as, "LBD 0-1; zero or one core sign of LBD, LBD 2-4: two more signs of LBD (parkinsonism, fluctuating cognition, RBD, balance problems)."
This makes it clear that the signs were assessed out of four, not six, and the balance problems and rigidity are extra information.
-In the survival in relation to medication, the fact that this was a cross-sectional analysis of medication use needs to be transparently emphasized, as this has marked implications for how to interpret this data. Suggest rewording to, "In the present study, there was no significant difference in overall survival months between those with and without antipsychotics as assessed at study entry (p=0.644)." Similarly, the sentence about anti-dementia medication should read, "Survival in relation to treatment with antidementia medication at study onset showed a trend…" -To clarify, could some of these patients had LBD? In the discussion, the authors state, "The fact that the prevalence of LBD signs was the strongest predictive factor suggests that some NH patients had undiagnosed LBD." But presumably at least some of these individuals had diagnosed LBD? -While I appreciate the authors' attempt to respond to reviewer #1's request for discussion regarding possible pathophysiology, the addition of the phrase "as a marker of reduced neurotransmitters due to alpha-synuclein engagement in the nuclei producing these" is confusing and not fully supported. I would suggest rewording to "as a marker of the severity of the underlying pathophysiology." The meaning of "alpha-synuclein engagement" is unclear and it is likely that the patholophysiology relates to both neurochemical changes and cell death.
-The confusing term "survival risk" remains in the conclusion (line 2 of conclusions); please reword as discussed in prior review -In the conclusion, the statement "These data support the notion that more thorough dementia investigations of the elderly living in NHs may lead to improved medical treatments and longer survival among this vulnerable population" remains unsupported and should be reworded. The value of this study is in prognosis, not treatment. There are no good treatments for fluctuating cognition or balance problems, so identifying these do not have a clear mechanism for prolonging survival. RBD can be treated, but it is likely that RBD symptoms are not leading to mortality but rather that the presence of RBD may represent more widespread or prominent disease. Rigidity can be treated to some extent if it is parkinsonian rigidity, but this could also represent contractures or deconditioning as can be seen in some individuals in NHs. Thus, it is not clear that identifying signs with the purpose of treating them will prolong survival. However, identifying these signs is very important for appropriate diagnosis and prognosis. The conclusions should focus on the ways this study is valuable rather than suggesting its value is in informing treatment, which may not change survival.
-This remains a study with valuable information and additional edits will help make the results and discussion more accessible to the readership.
VERSION 2 -AUTHOR RESPONSE
Reviewers comments Authors answers
Reviewer: 2 Reviewer Name: Melissa J. Armstrong, MD, MSc The authors have thoroughly addressed most of the reviewers' comments and the paper is improved while also maintaining its prior relevance.
In reviewing the edited manuscripts, the following could benefit from generally minor additional edits.
1 -In the abstract, suggest rewording to "Mean survival differed between the LBD groups; those with 0-1 LBD signs lived months longer than those with 2-4 LBD signs." This is a minor point. The main suggestion is to reclarify that the number refers to the number of signs, but I also feel that the living longer formulation reads a little easier. This is a very minor point and I am happy to defer to the authors.
We have changed as suggested, which improve the content.
2 -With the addition of HR CIs, the p-value is not needed (minor point, willing to leave to journal editorial discretion, but the CIs include the fact that the HR is statistically significant without the CI)
We agree and the p-value is removed. 3 -The meaning of "a high percentage of covering" in strength #2 is not entirely clear "a high percentage of covering" was changed to  "with data from 96% of the residents" 4 -To limitations I would add the cross-sectional nature of initial data collection in addition to the lack of a formal LBD diagnosis
We have added the suggested sentence for the limitation.
5
-The clarification about the first and second diagnostic levels for dementia diagnosis are very helpful. However, now that the authors clarify that 74% had a formal dementia diagnosis, this raises the question of what this means. If this means a formal etiologic diagnosis (eg AD, LBD, vascular), the percent for each formal diagnosis should be provided. If this means simply that they were formally reported as having dementia, it would be helpful to understand more about how this is different from the first diagnostic level. What is the difference between levels one and two? This is important for readers from different health care contexts to understand how
Residents from level one (26%) were formally reported as having dementia.
Residents from level two (74%) had a formal etiological diagnosis (which also was registered in hospital computerised data system); Dementia NOS 115(27%), AD 115 (27%), AD-mix 96(22%), VaD 85 (19%) and DLB/PDD 22(5%).
This has been added in table 1 as well as in methods  procedures "The first diagnostic level determines whether dementia is present and at the second level, the etiological dementia diagnosis is specified. In our study the the population in this study compares to the populations in the readers' own clinics.
formal etiological diagnoses were; dementia NOS (28%), AD (26%), AD-mix (22%), VaD (19%) and DLB/PDD (5%) [35] ." Therefore, reference number 35 was added.
6 -The response to reviewers explains the four clinical signs used to count the number of LBD symptoms, but I still don't see this explicitly described in the text. Suggest being explicit about this in the text or the legend with a sentence such as, "LBD 0-1; zero or one core sign of LBD, LBD 2-4: two more signs of LBD (parkinsonism, fluctuating cognition, RBD, balance problems)." This makes it clear that the signs were assessed out of four, not six, and the balance problems and rigidity are extra information.
The sentence "LBD 0-1; zero or one core sign of LBD, LBD 2-4: two more signs of LBD (parkinsonism, visual hallucinations, fluctuating cognition and RBD)." has been added under methods -> procedures.
7 -In the survival in relation to medication, the fact that this was a cross-sectional analysis of medication use needs to be transparently emphasized, as this has marked implications for how to interpret this data. Suggest rewording to, "In the present study, there was no significant difference in overall survival months between those with and without antipsychotics as assessed at study entry (p=0.644)." Similarly, the sentence about anti-dementia medication should read, "Survival in relation to treatment with anti-dementia medication at study onset showed a trend…"
We agree and after considering both reviewers comments, including calculating power, we decided to remove the medication parts in abstract, results, table, discussion and conclusion. We realised that it took away the focus of the main essence of our study, which is the LBD signs in relation to survival.
8
-To clarify, could some of these patients had LBD?
In the discussion, the authors state, "The fact that the prevalence of LBD signs was the strongest predictive factor suggests that some NH patients had undiagnosed LBD." But presumably at least some of these individuals had diagnosed LBD?
In the discussion, the mentioned sentence was changed to: "The fact that the prevalence of LBD signs was the strongest predictive factor for survival suggests that more than the formally LBD diagnosed 5 percent of the NH residents might have undiagnosed LBD."
See also number 5 9 While I appreciate the authors' attempt to respond to reviewer #1's request for discussion
The sentence "as a marker of reduced neurotransmitters due to alpha-synuclein regarding possible pathophysiology, the addition of the phrase "as a marker of reduced neurotransmitters due to alpha-synuclein engagement in the nuclei producing these" is confusing and not fully supported. I would suggest rewording to "as a marker of the severity of the underlying pathophysiology." The meaning of "alpha-synuclein engagement" is unclear and it is likely that the patholophysiology relates to both neurochemical changes and cell death.
engagement in the nuclei producing these" is removed from discussion  stenghts and limitations
The following text "This is in accordance with a neuropathological study by Fujishiro et al. [40] showing increased alfasynuclein pathology with increasing number of LBD core symptoms. In this study the core symptoms of the consensus criteria from 2005 (Parkinsonism, visual hallucinations, fluctuating alertness/cognition) were used complemented with RBD, the same signs which we used in our study." was added under discussion  survival in the LBD groups.
Therefore, we suggest increased number of LBD signs, as a marker of the severity of the underlying pathophysiology (alfasynuclein, Lewybodies and Lewyneurites).
10 -The confusing term "survival risk" remains in the conclusion (line 2 of conclusions); please reword as discussed in prior review
The term has been changed to "mortality risk"
11 -In the conclusion, the statement "These data support the notion that more thorough dementia investigations of the elderly living in NHs may lead to improved medical treatments and longer survival among this vulnerable population" remains unsupported and should be reworded.
The value of this study is in prognosis, not treatment. There are no good treatments for fluctuating cognition or balance problems, so identifying these do not have a clear mechanism for prolonging survival. RBD can be treated, but it is likely that RBD symptoms are not leading to mortality but rather that the presence of RBD may represent more widespread or prominent disease. Rigidity can be treated to some extent if it is parkinsonian rigidity, but this could also represent contractures or deconditioning as can be seen in some individuals in NHs. Thus, it is not clear that identifying signs with the purpose of treating them will prolong survival. However, identifying these signs is very important for
We agree and after considering both reviewers comments, including calculating power, we decided to remove the medication parts in abstract, results, table, discussion and conclusion.
We realised that it took away the focus of the main essence of our study, which is the LBD signs in relation to survival.
appropriate diagnosis and prognosis. The conclusions should focus on the ways this study is valuable rather than suggesting its value is in informing treatment, which may not change survival.
Reviewer We agree and after considering both reviewers comments, including calculating power, we decided to remove the medication parts in abstract, results, table, discussion and conclusion.
See also number 19 for the conclusion changes.
13 2. Strength and Limitations:
The reader needs to know the following limitations: -Cox regression models were only adjusted for
The limitations have been updated after suggestions from reviewer 1 and 2.
age and gender, but not for severity of dementia, co-morbidity, nor functioning -Baseline data for this study was collected cross-sectionally, and participants were at different stages of their disease.
14 3. Methods You described ascertaining ATC codes for anxiolytics, hypnotics/sedatives, antidepressants, but those were not used in the study.
We have under methods and medical data removed "anxiolytics (N05B), hypnotics/sedatives (N05C), antidepressants (N06A) " 15 4. Results It still remains a bit unclear what Table 3 shows. It seems to show hazard ratios for mortality in relation to baseline variables, but is labelled 'Mortality risk based on LBD group'.
We clarify Table 3 by changing headline/sentence to "Mortality risk based on baseline variables and LBD groups"
16 Table 3 also contains a variable about patients suffering from dementia; I thought all patients suffered from dementia. This might refer to a formal diagnosis, but this might not be a very meaningful variable in this data. I'm not sure whether a stratified analysis for medication hazards/benefits is possible in the LBD groups. E.g. the LBD 2-4 group only consists of 116 patients, and how many of these were actually prescribed an antipsychotic / antidementia drug? If you want to include this analysis, please first check that you have adequate study power to do so -and report in methods. And further whether an interaction exists between LBD group and antidementia drug/antipsychotic prescribing.
We agree and therefore the variable "Dementia" is removed from table 3.
See also number 5 17 5. Discussion Again, the study cannot make any conclusions about the treatment with antidementia/antidementia drugs on survival; only the observation that there doesn't seem to appear a difference between receivers / nonreceivers of the medications. This needs to be in particular be mentioned in the discussion chapter 'Survival in relation to medication'. In Anti-dementia medication: After the sentence 'However, only one-third of our study population were treated with antiWe agree and after considering both reviewers comments, including calculating power, we decided to remove the medication parts in abstract, results, The aforementioned points need to be added: -Cox regression models were only adjusted for age and gender, but not for severity of dementia, co-morbidity, nor functioning -Baseline data for this study was collected cross-sectionally, and participants were at different stages of their disease.
We agree and updated according to the suggestions under discussion  strengths and limitations 19 The statement 'Finally, a finding that increases confidence in our mortality risk results based on number of LBD signs is that antipsychotic treatments did not appear to influence mortality. This supports our hypothesis that survival among elderly patients in the LBD 2-4 group is not influenced by antipsychotics but rather by the signs of LBD as a marker of reduced neurotransmitters due to alfa-synuclein engagement in the nuclei producing these.' still appears very odd. As adverse reactions to antipsychotics are a hallmark of LBD, the finding that patients with LBD didn't have that, it would certainly not increase confidence in the results.
I suspect that the finding that antipsychotics don't affect mortality in the LBD 2-4 group is due to a type 2 error, but please check that the study is adequately powered.
Conclusions: 'We did not find a negative effect of antipsychotics on survival.' needs to be toned down We agree and after considering both reviewers comments, including calculating power, we decided to remove the medication parts in results, table, discussion and conclusion. We realised that it took away the focus of the main essence of our study, that is the LBD signs in relation to survival Accordingly, the conclusion has been changed.
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